HK1142898A1 - 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine- beta-hydroxylase - Google Patents

1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine- beta-hydroxylase

Info

Publication number
HK1142898A1
HK1142898A1 HK10109325.5A HK10109325A HK1142898A1 HK 1142898 A1 HK1142898 A1 HK 1142898A1 HK 10109325 A HK10109325 A HK 10109325A HK 1142898 A1 HK1142898 A1 HK 1142898A1
Authority
HK
Hong Kong
Prior art keywords
alkyl
dihydroimidazole
hydroxylase
dopamine
inhibitors
Prior art date
Application number
HK10109325.5A
Other languages
English (en)
Inventor
Da Silva Patricio Manuel Vieira Araujo Soares
David Alexander Learmonth
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1142898(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of HK1142898A1 publication Critical patent/HK1142898A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK10109325.5A 2007-05-08 2010-09-29 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine- beta-hydroxylase HK1142898A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
HK1142898A1 true HK1142898A1 (en) 2010-12-17

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10109325.5A HK1142898A1 (en) 2007-05-08 2010-09-29 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine- beta-hydroxylase

Country Status (30)

Country Link
US (5) US8481582B2 (pt)
EP (1) EP2155731B1 (pt)
JP (1) JP5559677B2 (pt)
KR (1) KR101598482B1 (pt)
CN (1) CN101687858B (pt)
AR (2) AR066457A1 (pt)
AT (1) ATE499367T1 (pt)
AU (1) AU2008246443B2 (pt)
BR (1) BRPI0811275B8 (pt)
CA (1) CA2686387C (pt)
CL (1) CL2008001321A1 (pt)
CY (1) CY1111517T1 (pt)
DE (1) DE602008005141D1 (pt)
DK (1) DK2155731T3 (pt)
ES (1) ES2360841T3 (pt)
GB (1) GB0708818D0 (pt)
HK (1) HK1142898A1 (pt)
HR (1) HRP20110253T1 (pt)
IL (1) IL201921A (pt)
MX (1) MX2009012041A (pt)
NO (1) NO20093275L (pt)
NZ (1) NZ580962A (pt)
PL (1) PL2155731T3 (pt)
RS (1) RS51692B (pt)
RU (1) RU2501796C2 (pt)
SI (1) SI2155731T1 (pt)
TW (1) TWI458722B (pt)
UA (1) UA104844C2 (pt)
WO (1) WO2008136695A1 (pt)
ZA (1) ZA200908612B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
PT2655363T (pt) 2010-12-22 2017-07-13 Bial-Portela & Ca S A Formas cristalinas e processos para a sua preparação
EP2726454B1 (en) * 2011-06-29 2018-01-24 Bial-Portela & CA, S.A. Process
CA2890920C (en) 2012-11-14 2020-12-15 Bial - Portela & Ca, S.A. 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) * 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
TWI790281B (zh) 2017-09-13 2023-01-21 美商安進公司 雙醯胺肌節活化化合物及其用途
US11434242B2 (en) 2017-12-04 2022-09-06 Bial—Portela & Ca, S.A. Dopamine-b-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
WO1995029165A2 (en) * 1994-04-26 1995-11-02 Syntex (U.S.A.) Inc. Benzocycloalkylaz0lethione derivatives as dopamin beta-hydroxylase inhibitors
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
US20170369478A1 (en) 2017-12-28
IL201921A0 (en) 2010-06-16
CA2686387C (en) 2015-06-30
AU2008246443A8 (en) 2010-01-07
IL201921A (en) 2013-11-28
NZ580962A (en) 2012-05-25
TW200918525A (en) 2009-05-01
KR20100017546A (ko) 2010-02-16
MX2009012041A (es) 2010-02-18
US20210261533A1 (en) 2021-08-26
ATE499367T1 (de) 2011-03-15
US8481582B2 (en) 2013-07-09
AU2008246443B2 (en) 2013-07-11
DE602008005141D1 (de) 2011-04-07
ES2360841T3 (es) 2011-06-09
RU2009145270A (ru) 2011-06-20
ZA200908612B (en) 2010-11-24
US9630951B2 (en) 2017-04-25
DK2155731T3 (da) 2011-05-02
US20130345275A1 (en) 2013-12-26
RU2501796C2 (ru) 2013-12-20
JP2010526136A (ja) 2010-07-29
EP2155731A1 (en) 2010-02-24
NO20093275L (no) 2010-02-04
EP2155731B1 (en) 2011-02-23
CN101687858A (zh) 2010-03-31
CN101687858B (zh) 2012-12-26
CY1111517T1 (el) 2015-08-05
KR101598482B1 (ko) 2016-02-29
BRPI0811275B8 (pt) 2021-05-25
AR066457A1 (es) 2009-08-19
US20190322648A1 (en) 2019-10-24
WO2008136695A1 (en) 2008-11-13
US20100137390A1 (en) 2010-06-03
BRPI0811275B1 (pt) 2020-01-07
AR112789A2 (es) 2019-12-11
BRPI0811275A2 (pt) 2014-12-23
JP5559677B2 (ja) 2014-07-23
HRP20110253T1 (hr) 2011-05-31
CL2008001321A1 (es) 2008-12-26
UA104844C2 (uk) 2014-03-25
AU2008246443A1 (en) 2008-11-13
SI2155731T1 (sl) 2011-05-31
TWI458722B (zh) 2014-11-01
PL2155731T3 (pl) 2011-07-29
GB0708818D0 (en) 2007-06-13
RS51692B (en) 2011-10-31
CA2686387A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
HK1142898A1 (en) 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine- beta-hydroxylase
MY143578A (en) Piperazinediones as oxytocin receptor antagonists
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
GEP20125581B (en) Sulfonyl amide derivatives for treatment of abnormal cell growth
HK1091121A1 (en) Substituted 2-aminotetralins for the treatment of depressions
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
SE0401971D0 (sv) Piperidne derivatives
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
WO2009066041A3 (fr) Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1911757A3 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
BR0315580A (pt) Derivados de metileno uréia
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
MY151072A (en) Heteroaryl derivative
WO2008157404A3 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
MX2009013003A (es) Derivados de piperidina-amida.
WO2008106125A3 (en) Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220504